株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

子宮頸部上皮内腫瘍 (CIN) : パイプライン分析

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 350598
出版日 ページ情報 英文 133 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.10円で換算しております。
子宮頸部上皮内腫瘍 (CIN) : パイプライン分析 Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019
出版日: 2019年12月16日 ページ情報: 英文 133 Pages
概要

子宮頸部上皮内腫瘍(CIN)は、子宮頸部異形成とも呼ばれ、子宮頸部表面の細胞に異形を生じて発生し、25歳から35歳までの女性によく見られる疾患です。ほとんどの場合ヒトパピローマウィルス (HPV)が原因で発症します。素因としては免疫抑制剤や喫煙が挙げられます。症候には陰部疣贅、出血異常、性交後出血、膣帯下、腰痛などがあります。 生殖いぼ、異常な出血、関係の後のスポッティング、膣の解放とを含みます。

当レポートでは、子宮頸部上皮内腫瘍(CIN)の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

子宮頸部上皮内腫瘍 (CIN) 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

パイプライン製品の概況

  • 臨床段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • CEL-SCI Corporation
  • Helix BioPharma Corp.
  • Inovio Pharmaceuticals, Inc.
  • PDS Biotechnology Corporation
  • Vaccibody AS

治療薬の評価

  • 単剤製品別
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Altum Pharmaceuticals Inc, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Antiva Biosciences Inc, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Bioleaders Corp, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Brooklyn ImmunoTherapeutics LLC, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corp, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Douglas Pharmaceuticals Ltd, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Elicio Therapeutics, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine Inc, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by GenoLac BL Corp, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Hefei Ruichengsheng Biotechnology Co Ltd, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by KinoPharma Inc, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Novan Inc, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Papivax LLC, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corp, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Redbiotec AG, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Bovax Biotechnology Co Ltd, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Institute of Biological Products Co Ltd, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Transgene SA, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccibody AS, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaxart Inc, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Pipeline by ViciniVax BV, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H2 2019
  • Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
目次
Product Code: GMDHC11749IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline landscape.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 14, 6, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 2 and 4 molecules, respectively.

Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Cervical Intraepithelial Neoplasia (CIN) - Overview
  • Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
  • Altum Pharmaceuticals Inc
  • Antiva Biosciences Inc
  • Bioleaders Corp
  • Brooklyn ImmunoTherapeutics LLC
  • CEL-SCI Corp
  • Douglas Pharmaceuticals Ltd
  • Elicio Therapeutics
  • Genexine Inc
  • GenoLac BL Corp
  • Hefei Ruichengsheng Biotechnology Co Ltd
  • Inovio Pharmaceuticals Inc
  • KinoPharma Inc
  • Novan Inc
  • Papivax LLC
  • PDS Biotechnology Corp
  • Redbiotec AG
  • Shanghai Bovax Biotechnology Co Ltd
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shanghai Institute of Biological Products Co Ltd
  • THEVAX Genetics Vaccine USA Inc
  • Transgene SA
  • Vaccibody AS
  • Vaxart Inc
  • ViciniVax BV
  • Cervical Intraepithelial Neoplasia (CIN) - Drug Profiles
  • (bizalimogene ralaplasmid + mavilimogene ralaplasmid) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (lopinavir + ritonavir) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ABI-1968 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aminolevulinic acid hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AP-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BLSILSB-710c - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BLSPGAC-10 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Human Papillomavirus Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy to Target HPV Protein E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • efineptakin alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GLBL-101c - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GX-188E - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • human papillomavirus (9 valent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • human papillomavirus [serotypes 16, 18, 52, 58] (tetravalent, virus like particle) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IGMKK-16E7 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IRX-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Multikine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NSC-721689 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PDS-0101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PVX-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PVX-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RKP-00156 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RONC-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tipapkinogene sovacivec - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TVGV-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia And HPV Associated Head And Neck Squamous Cell Carcinoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VB-1016 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VED-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vvax-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VXAHPV-16.1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • WH-504 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • WH-602 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZFN-603 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZFN-758 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects
  • Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products
  • Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 03, 2019: PDS Biotechnology to present at the 12th Annual LD Micro Main Event
  • Nov 25, 2019: PDS Biotechnology to present at the World Vaccine & Immunotherapy Congress West Coast 2019
  • Nov 06, 2019: PDS Biotechnology accepted for oral presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting
  • Oct 01, 2019: PDS Biotechnology prioritizes development of PDS0101 in advanced cancers following promising phase 1 clinical outcome data
  • Sep 19, 2019: PDS Biotechnology reports clinical data for its novel immunotherapy PDS0101 in follow up to phase 1 human trial
  • Jun 26, 2019: Inovio completes enrollment of VGX-3100 phase 3 trial (reveal 1) for the treatment of HPV-related cervical pre-cancer
  • Jun 05, 2019: Peer-reviewed publication confirms the potential of Transgene' TG4001
  • May 06, 2019: Inovio receives European Medicines Agency Certification for quality and non-clinical data for its Phase 3 product, VGX-3100
  • Apr 17, 2019: Inovio's phase 3 HPV immunotherapy selected as "Best Therapeutic Vaccine" at World Vaccine Congress
  • Apr 03, 2019: Therapy completely clears HPV in one-third of cervical precancers
  • Mar 25, 2019: Positive 12-month results from phase Iia clinical study in high grade cervical dysplasia provides proof-of-concept for Vaccibody's immunotherapy platform and lead candidate VB1O.16
  • Feb 27, 2019: vaccibody as to present data on vb10.16 at upcoming American Association for Cancer Research Annual Meeting
  • Dec 06, 2018: Study tests new vaccine for precancerous cervical cells
  • Apr 26, 2018: Vaccibody Announces Strong Killer T Cell Responses (Cd8+) In Vb10.16 Vaccinated Patients Further Strengthening The Strong Potential Of Their Vaccine Technology Platform; Presenting At European Neoantigen Summit Amsterdam
  • Feb 14, 2018: IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer